These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 11488362)

  • 1. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
    Feighner JP; Entsuah AR; McPherson MK
    J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
    Meoni P; Salinas E; Brault Y; Hackett D
    J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
    Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC
    J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 12. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
    Lydiard RB; Pitrosky B; Hackett D; White C
    J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
    Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
    Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
    Rickels K; Pollack MH; Sheehan DV; Haskins JT
    Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
    Costa e Silva J
    J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
    Rynn MA; Riddle MA; Yeung PP; Kunz NR
    Am J Psychiatry; 2007 Feb; 164(2):290-300. PubMed ID: 17267793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
    Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
    J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.